NICE Single Technology Appraisal Guidance No 255 – Cabazitaxel
for hormone-refractory metastatic prostate cancer previously
treated with a docetaxel-containing regimen
This NICE guidance was published on 11 May 2012.
The web reference for the appraisal and other related documents is:
NHSScotland should note
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (735/11) on
this medication for this indication in October 2011. This stated
cabazitaxel solution for infusion
(Jevtana®) is not recommended for use within NHS Scotland
in combination with prednisone or prednisolone for the treatment of
patients with hormone refractory metastatic prostate cancer
previously treated with a docetaxel-containing regimen.
Access the advice of SMC
3. There is no material difference between the
recommendations of the NICE STA and SMC.
If you need further assistance, please contact
Eleanor Brownlee in
the first instance
Published Date: 11 May 2012